Judge Compels Glaxo CEO To Answer Questions In Challenge To AZT Patent

Law360, New York (April 4, 2005, 12:00 AM EDT) -- A California federal court has ruled that GlaxoSmithKline's chief executive officer must answer further questions in a deposition in a challenge to its patent rights to AZT (Retrovir), the first AIDS drug.

As part of the legal proceedings, attorneys for plaintiff AIDS Healthcare Foundation (AHF) deposed Glaxo CEO Jean-Pierre Garnier in late January 2005 in Philadelphia. AHF said Garnier left questions unanswered during that deposition, prompting its attorneys to petition the court to be able to continue Garnier's deposition.

In late March, U.S. Court Magistrate Judge...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.